Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18597323 | 0.82 | CYP3A4 (0.42) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL49570 | 0.80 | SIGMAR1 (0.47) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21102318 | 0.80 | SIGMAR1 (0.47) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15274890 | 0.80 | SIGMAR1 (0.47) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL722841 | 0.79 | GABRA1 (0.47) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24389142 | 0.79 | CYP3A4 (0.56) | CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL944030 | 0.78 | SIGMAR1 (0.46) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7053823 | 0.78 | SIGMAR1 (0.46) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL21148333 | 0.77 | SIGMAR1 (0.39) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23074239 | 0.77 | SIGMAR1 (0.36) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1246296-C | Process for preparing 2-ethyl-N-(ethoxy methyl)-alpha-chloroacetanilide | WANG ZHENGQUAN (CN) | 2006-03-22 | — | — | CN | claimed |
| CN-1532183-A | Process for preparing 2-ethyl-N-(ethoxy methyl)-alpha-chloroacetanilide | 王正权 | 2004-09-29 | — | — | CN | claimed |
| CN-1401630-A | Preparation method of 2-ethyl-N- (ethoxymethyl) -a-chloroacetanilide | WANG ZHENGQUAN (CN) | 2003-03-12 | — | — | CN | claimed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9682080-B2 | Pyruvate kinase activators for use in therapy | AGIOS PHARMACEUTICALS, INC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-2332905-B1 | BCRP/ABCG2 Inhibitor | YAKULT HONSHA KK (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160069649-A1 | BALLISTIC RESISTANT ARTICLE, SEMI-FINISHED PRODUCT FOR AND METHOD OF MAKING A SHELL FOR A BALLISTIC RESISTANT ARTICLE | TEIJIN ARAMID B.V. (NL) | 2016-03-10 | — | — | US | disclosed |
| EP-2558461-B1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL MYERS SQUIBB CO (US) | 2015-12-02 | — | — | EP | disclosed |
| US-8993087-B2 | Ballistic-resistant articles | TEIJIN ARAMID B.V. (NL) | 2015-03-31 | — | — | US | disclosed |
| US-20120255430-A1 | BALLISTIC-RESISTANT ARTICLES | TEIJIN ARAMID B.V. (NL) | 2012-10-11 | — | — | US | disclosed |
| US-20080280877-A1 | Azetidines | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
| CN-1246296-C | Process for preparing 2-ethyl-N-(ethoxy methyl)-alpha-chloroacetanilide | WANG ZHENGQUAN (CN) | 2006-03-22 | — | — | CN | disclosed |
| CN-1532183-A | Process for preparing 2-ethyl-N-(ethoxy methyl)-alpha-chloroacetanilide | 王正权 | 2004-09-29 | — | — | CN | disclosed |
| CN-1401630-A | Preparation method of 2-ethyl-N- (ethoxymethyl) -a-chloroacetanilide | WANG ZHENGQUAN (CN) | 2003-03-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | SIGMAR1 3980/4885GRIN2D 4878/4885GRIN3B 3844/4885 |
| US-20080280877-A1 | Azetidines | PTGER2, PTGER1, PTGDR2 | SIGMAR1 629/4885GRIN2D 1374/4885GRIN3B 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.